Sun Pharmaceutical Industries Limited (SUNPHARMA) — Financial Results | 1 August 2025

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Sun Pharmaceutical reported consolidated Q1 FY2026 revenue of ₹3,570.35 crores, up 24.6% YoY from ₹2,867.85 crores. Net profit after tax rose to ₹444.62 crores from ₹538.48 crores YoY, while profit before tax declined to ₹540.49 crores from ₹661.34 crores. Earnings per share fell to ₹10.62 (basic) from ₹13.39. The company published unaudited quarterly results in newspapers on July 31, 2025.

📄 View Original Announcement (PDF)

About Sun Pharmaceutical Industries Limited (SUNPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹4,50,643.09 Cr P/E: 41.3 ROE: 15.1% ROCE: 20.3%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

📊 More SUNPHARMA filings

See all SUNPHARMA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SUNPHARMA — Free

Free account · 2 AI queries/day